GLAND PHARMA Financial Statement Analysis
|
||
|
The Revenues of GLAND PHARMA have decreased by -0.85% YoY .
The Earnings Per Share (EPS) of GLAND PHARMA has increased by 47.05 % YoY. |
||
GLAND PHARMA Last 5 Annual Financial Results
[BOM: 543245|NSE : GLAND]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹5,617 Cr | ₹5,665 Cr | ₹3,625 Cr | ₹4,401 Cr | ₹3,463 Cr |
| Expenses | ₹4,348 Cr | ₹4,332 Cr | ₹2,600 Cr | ₹2,891 Cr | ₹2,161 Cr |
| Operating Profit (Excl OI) | ₹1,269 Cr | ₹1,333 Cr | ₹1,025 Cr | ₹1,510 Cr | ₹1,302 Cr |
| Other Income | ₹214 Cr | ₹170 Cr | ₹240 Cr | ₹224 Cr | ₹135 Cr |
| Interest | ₹42 Cr | ₹26 Cr | ₹7.45 Cr | ₹5.24 Cr | ₹3.41 Cr |
| Depreciation | ₹378 Cr | ₹345 Cr | ₹147 Cr | ₹110 Cr | ₹99 Cr |
| Profit Before Tax | ₹1,063 Cr | ₹1,133 Cr | ₹1,055 Cr | ₹1,619 Cr | ₹1,335 Cr |
| Profit After Tax | ₹699 Cr | ₹772 Cr | ₹781 Cr | ₹1,212 Cr | ₹997 Cr |
| Consolidated Net Profit | ₹699 Cr | ₹772 Cr | ₹781 Cr | ₹1,212 Cr | ₹997 Cr |
| Earnings Per Share (Rs) | ₹62.35 | ₹42.40 | ₹46.90 | ₹47.42 | ₹73.75 |
| PAT Margin (%) | 15.98 | 12.44 | 13.64 | 21.55 | 27.53 |
| ROE(%) | 10.56 | 7.82 | 9.26 | 10.34 | 18.61 |
| ROCE(%) | 14.96 | 11.97 | 13.63 | 14.04 | 24.85 |
| Total Debt/Equity(x) | 0.02 | 0.03 | 0.04 | 0.00 | 0.00 |
Key Financials |
||
| Market Cap | : | ₹ 48,250.1 Cr |
| Revenue (TTM) | : | ₹ 6,725.3 Cr |
| Net Profit(TTM) | : | ₹ 1,128.8 Cr |
| EPS (TTM) | : | ₹ 68.4 |
| P/E (TTM) | : | 42.7 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| GLAND PHARMA | 3.2% | 7.4% | 31.4% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.4% | 0.9% | 19.6% |
| DIVIS LABORATORIES | -1.2% | 21.1% | 29.7% |
| TORRENT PHARMACEUTICALS | -2.3% | 0.3% | 34.8% |
| CIPLA | 0.7% | 1.5% | -2% |
| DR REDDYS LABORATORIES | -0.3% | -7.1% | -3.9% |
| MANKIND PHARMA | -0.9% | -3.4% | -4.8% |
| LUPIN | -4.3% | -8.9% | 26.5% |
| ZYDUS LIFESCIENCES | 0.2% | -2.6% | 17.5% |
GLAND PHARMA Revenues
[BOM: 543245|NSE : GLAND]
| Y-o-Y | -0.85 % |
| 5 Yr CAGR | 12.85 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹5,617 Cr | -0.85 | |
| Mar2025 | ₹5,665 Cr | 56.29 | |
| Mar2024 | ₹3,625 Cr | -17.64 | |
| Mar2023 | ₹4,401 Cr | 27.08 | |
| Mar2022 | ₹3,463 Cr | - | |
GLAND PHARMA Operating Profit
[BOM: 543245|NSE : GLAND]
| Y-o-Y | -4.81 % |
| 5 Yr CAGR | -0.65 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,269 Cr | -4.81 | |
| Mar2025 | ₹1,333 Cr | 30.09 | |
| Mar2024 | ₹1,025 Cr | -32.14 | |
| Mar2023 | ₹1,510 Cr | 15.97 | |
| Mar2022 | ₹1,302 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -3.99 % |
| 5 Yr CAGR | -11.97 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 22.59% | -3.99 | |
| Mar2025 | 23.53% | -16.77 | |
| Mar2024 | 28.27% | -17.63 | |
| Mar2023 | 34.32% | -8.75 | |
| Mar2022 | 37.61% | - | |
GLAND PHARMA Profit After Tax
[BOM: 543245|NSE : GLAND]
| Y-o-Y | -9.57 % |
| 5 Yr CAGR | -8.51 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹699 Cr | -9.57 | |
| Mar2025 | ₹772 Cr | -1.10 | |
| Mar2024 | ₹781 Cr | -35.54 | |
| Mar2023 | ₹1,212 Cr | 21.54 | |
| Mar2022 | ₹997 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 28.46 % |
| 5 Yr CAGR | -12.71 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 15.98 % | 28.46 | |
| Mar2025 | 12.44 % | -8.80 | |
| Mar2024 | 13.64 % | -36.71 | |
| Mar2023 | 21.55 % | -21.72 | |
| Mar2022 | 27.53 % | - | |
GLAND PHARMA Earnings Per Share (EPS)
[BOM: 543245|NSE : GLAND]
| Y-o-Y | 47.05 % |
| 5 Yr CAGR | -4.11 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹62 | 47.05 | |
| Mar2025 | ₹42 | -9.59 | |
| Mar2024 | ₹47 | -1.10 | |
| Mar2023 | ₹47 | -35.70 | |
| Mar2022 | ₹74 | - | |
GLAND PHARMA Return on Capital Employed (ROCE)
[BOM: 543245|NSE : GLAND]
| Y-o-Y | 24.98 % |
| 5 Yr CAGR | -11.92 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 14.96% | 24.98 | |
| Mar2025 | 11.97% | -12.18 | |
| Mar2024 | 13.63% | -2.92 | |
| Mar2023 | 14.04% | -43.50 | |
| Mar2022 | 24.85% | - | |
GLAND PHARMA Share Price vs Sensex
| Current Share Price | : | ₹2,924.3 |
| Current MarketCap | : | ₹ 48,250.1 Cr |
| Updated EOD on | : | Aug 11,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAND PHARMA | 3.2% |
7.4% |
31.4% |
| SENSEX | -0.4% |
0.8% |
-3% |
GLAND PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 250 SMALLCAP INDEX | 1.2% | 1.5% | 7.5% |
| BSE HEALTHCARE | 1.1% | 2.9% | 16% |
| BSE 400 MIDSMALLCAP INDEX | 0.9% | 1.6% | 9.4% |
| BSE 1000 | 0.3% | 1.5% | 4.5% |
| BSE 500 | 0.3% | 1.4% | 4% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY SMALLCAP 50 | 2% | 3.3% | 16.7% |
| NIFTY SMALLCAP250 MOMENTUM QUALITY 100 INDEX | 1.9% | 2% | 8.1% |
| NIFTY MIDSMALL HEALTHCARE | 1.6% | 3.2% | 18.4% |
| NIFTY MIDSMALLCAP400 MOMENTUM QUALITY 100 INDEX | 1.3% | 2.6% | 8.5% |
| NIFTY SMALLCAP 500 | 1.2% | 1.7% | NA |
You may also like the below Video Courses
FAQ about GLAND PHARMA Financials
How the annual revenues of GLAND PHARMA have changed ?
The Revenues of GLAND PHARMA have decreased by -0.85% YoY .
How the Earnings per Share (EPS) of GLAND PHARMA have changed?
The Earnings Per Share (EPS) of GLAND PHARMA has increased by 47.05 % YoY .
Check out Intrinsic Value of Peers of GLAND PHARMA
Compare Stock Analytics of Peers of GLAND PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
